Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MEDI8367 in Healthy and CKD Subjects
NCT04365218Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2020
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MEDI8367 in chronic kidney disease (CKD) (6 cohorts), sponsored by AstraZeneca. Primary endpoints: Number of subjects with adverse events (AEs) and serious adverse events (SAEs), Number of subjects with abnormal systolic blood pressure (SBP) and 11 more. Started Jul 2020; status: completed.
02
Drugs
MEDI8367
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04365218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04365218.